Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 9/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.44 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.43 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14722731 | 0.85 | IGF1R (0.50) | IGF1RCCNA2CDK2CCNA1NEK1 | |
| SCHEMBL2319952 | 0.82 | PIK3C3 (0.55) | IGF1RCCNA2CDK2CCNA1NEK1 | |
| SCHEMBL5816922 | 0.81 | PIK3C3 (0.54) | IGF1RCCNA2CDK2CCNA1NEK1 | |
| SCHEMBL3853457 | 0.81 | IGF1R (0.53) | IGF1RCCNA2CDK2CCNA1NEK1 | |
| SCHEMBL2321718 | 0.80 | IGF1R (0.68) | IGF1R | |
| SCHEMBL24350501 | 0.79 | PIK3C3 (0.54) | IGF1RPIK3C3NTRK1 | |
| SCHEMBL22917390 | 0.77 | PIK3C3 (0.50) | IGF1RNEK1PIK3C3 | |
| SCHEMBL29539700 | 0.77 | PIK3C3 (0.50) | IGF1RNEK1PIK3C3 | |
| SCHEMBL3854177 | 0.77 | IGF1R (0.52) | IGF1RCCNA2CDK2CCNA1NTRK1 | |
| SCHEMBL5770155 | 0.77 | IGF1R (0.49) | IGF1RNEK1PIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2748159-A1 | SERINE/THREONINE PAK1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-07-02 | — | — | EP | disclosed |
| US-8637537-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20130225620-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| WO-2013026914-A1 | SERINE/THREONINE PAK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225620-A1 | SERINE/THREONINE KINASE INHIBITORS | PAK1, AKT1, RB1 | IGF1R 584/4885CCNA2 357/4885CDK2 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.